<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>School of Life Sciences</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/48C13E55-28C1-4AE4-BA67-521BE128FE74"><gtr:id>48C13E55-28C1-4AE4-BA67-521BE128FE74</gtr:id><gtr:firstName>Graeme</gtr:firstName><gtr:surname>Milligan</gtr:surname><gtr:orcidId>0000-0002-6946-3519</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0900050"><gtr:id>91E9664F-8D7C-4328-BA8E-D415357E8978</gtr:id><gtr:title>The organisational structure of class A GPCRs: Implications for function and drug design</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0900050</gtr:grantReference><gtr:abstractText>A substantial fraction of therapeutic medicines that are used to treat conditions as wide ranging as heart failure, elevated blood pressure, asthma, and schizophrenia act by either activating or inhibiting members of a family of proteins known as G protein-coupled receptors. These recognise the presence of extracellular hormones and neuro-transmitters and convert this information into signals that allow cells to respond. As well as the members of the G protein-coupled receptor family that are the molecular targets of current medicines, there are many more that are being actively explored to understand the details of their function and their potential roles in the development or modulation of disease. For many years it was considered that G protein-coupled receptors existed and functioned as monomers. However, a wide range of recent studies have indicated that this is probably incorrect and that as well as interacting with themselves to form homo-dimers, different members of the G protein-coupled receptor family that are present in the same cell may interact to form hetero-dimers. This may have important consequences both for understanding the action of currently used drugs and, more importantly, in the manner in which novel therapeutic medicines are identified and developed. The proposal plans to build on the insights my team and I have developed in this area over the past 5 years to understand the molecular basis of how and where G protein-coupled receptor homo-and hetero-dimers form and may be regulated and to take advantage of the identification of a number of hetero-dimer-selective ligands to understand the basis of this selectivity. This is likely to contribute to the development of novel medicines with greater selectivity and more limited side effects.</gtr:abstractText><gtr:technicalSummary>G protein-coupled receptors (GPCRs) are the largest family of transmembrane receptors and the most successfully exploited for the development of therapeutically active, small molecule medicines. All of the currently employed medicines that target GPCRs have been identified and developed based on the presumption that GPCRs exist and function as monomeric species. However, although it has been established that some rhodopsin-family GPCRs can function as monomers, in recent times it has also been established that most, if not all, GPCRs exist in cells as dimers or higher-order complexes. As well as self-associations that generate homo-dimers/oligomers, there is also the potential for interactions between certain pairs of co-expressed GPCRs to generate hetro-dimers/oligomers. As a number of these display distinct regulation and pharmacology, they may represent novel sets of drug targets. A large number of key questions remain, however, before this potential may be realised. This application will employ both current and developing methodologies that require substantial optimisation to explore the quaternary structure of both homo-and hetero-dimers of class A GPCRs at distinct points in their life cycle. 
Central points that I will adress include: (1) the molecular basis of alpha1-adrenoceptor homo-dimerisation and the minimum size of the complex, (2) if activation of class A GPCR homo-dimers results in signal generation via ?trans-activation? between the component protomers,(3) the allosteric regulation of GPCR hetero-dimers/oligomers, (4) the pharmacological basis of hetero-dimer/oligomer selective ligands and
(5) the molecular basis and size of GPCR hetero-dimers/oligomers.</gtr:technicalSummary><gtr:fund><gtr:end>2014-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1784822</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Talks at International meetings</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E8542047-62A9-4F76-A875-821AFF1566BF</gtr:id><gtr:impact>I give a large number of seminars at conferences, at University departments and to Pharmaceutical/biotechnology companies. One I have listed the date above for was 'Novel Assay Technologies for the Discovery of GPCR Drugs&amp;quot;, Screening Europe Conference, Barcelona, Spain. Keynote Presentation

In in the perio 2008-2013 I have given more than 50 such presentations

Press conference</gtr:impact><gtr:outcomeId>9538D47599C</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture to Industry meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2AE281DF-6960-4810-AC96-BD28E5A6C049</gtr:id><gtr:impact>Approx 200 researchers predominantly from the Pharma/Biotech sector attend annually a series of meetimngs at the interface of industrial and academic research in this area.

I was subsequently invited to discuss issues and topics arising by a number of Pharma companies</gtr:impact><gtr:outcomeId>QngQqVSKfUn</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2009,2010,2011,2012,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>28117</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust 'Value in People' Awards</gtr:description><gtr:end>2008-08-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>1A105219-DBAA-4A1D-B79D-5A63364A2B33</gtr:id><gtr:outcomeId>7CAC53FD7630</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>416349</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Project Grant (Exploring the selectivity and consequences of GPCR homo and hetero- dimerisation/oligomerisation using RASSLs)</gtr:description><gtr:end>2010-04-02</gtr:end><gtr:fundingOrg>CHDI Foundation</gtr:fundingOrg><gtr:id>CFD3573D-59A4-4D75-A743-5B7B31C36B15</gtr:id><gtr:outcomeId>FE539E6C1C40</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member Nomenclature committee-International Union of Basic and Clinical Pharmacology</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>512AF06A-CBB4-4224-8A0B-265B2F876C4D</gtr:id><gtr:outcomeId>55FE31E3F22</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Links a G protein-coupled receptor to a G protein to produce a single open reasding frame incorporating both functionalities</gtr:description><gtr:id>359910DF-CD3B-4F4F-8877-874B2CE4E1FE</gtr:id><gtr:impact>Used in drug screening and a variation of this resulted in the submission of a patent that has bene licensed by two pharmaceutical companies</gtr:impact><gtr:outcomeId>CE5DEC0C9BB</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>GPCR-G protein fusions</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The G Protein Coupled Receptor Oligomer Knowledge Base.</gtr:description><gtr:id>34200526-156D-40D4-9874-023981A751E4</gtr:id><gtr:impact>This is dificult to assess. Rapid expansion of available data about G Protein Coupled Receptor (GPCR) dimers/oligomers over the past few years requires an effective system to organize this information electronically. Based on an ontology derived from a community dialogue involving colleagues using experimental and computational methodologies, we developed the GPCR-Oligomerization Knowledge Base (GPCR-OKB). GPCR-OKB is a system that supports browsing and searching for GPCR oligomer data. Such data were manually derived from the literature. While focused on GPCR oligomers, GPCR-OKB is seamlessly connected to GPCRDB, facilitating the correlation of information about GPCR protomers and oligomers. Availability and Implementation: The GPCR-OKB web application is freely available at http://www.gpcr-okb.org</gtr:impact><gtr:outcomeId>awz3fR3SUNZ</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>GPCR-OKB:</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:url>http://www.gpcr-okb.org</gtr:url><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Cell lines that stably express or can be induced to express G protein-coupled receptors linked to a suitable reporter gene, this may be a fluorescent polypeptide, e.g. GFP or a enzyme e.g. luciferase.</gtr:description><gtr:id>D324D829-D1D6-49DD-9CE1-83F9AB72001E</gtr:id><gtr:impact>Such reagents/cells lines are used widely in academic research, and in drug screening.</gtr:impact><gtr:outcomeId>9D99A0D2921</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Flp-In cell lines</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have generated a wide range of cell lines able to indicibly express one GPCR in the face of constant levels of expression of a second. These have been enginnered ot allow details analysis of protein-protein interactions using various FRET technologies.</gtr:description><gtr:id>35018831-1652-4108-AE24-53AB58C9D884</gtr:id><gtr:impact>Too early but joint experiments are underway.</gtr:impact><gtr:outcomeId>TVZPBuy8h19</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Double stables of GPCR oligomers</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>0D4ACD1D-ED3B-4FA7-AD06-13A4C3216CE2</gtr:id><gtr:title>The prevalence, maintenance, and relevance of G protein-coupled receptor oligomerization.</gtr:title><gtr:parentPublicationTitle>Molecular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85edc80268ea9bd4f3ba733ee9f05be5"><gtr:id>85edc80268ea9bd4f3ba733ee9f05be5</gtr:id><gtr:otherNames>Milligan G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0026-895X</gtr:issn><gtr:outcomeId>pm_15132_22_23632086</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF55BE10-EF01-4AD9-8BF6-7E59F1BD5CDE</gtr:id><gtr:title>Intramolecular fluorescence resonance energy transfer (FRET) sensors of the orexin OX1 and OX2 receptors identify slow kinetics of agonist activation.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bcc2284555def528ab993e8adea04d60"><gtr:id>bcc2284555def528ab993e8adea04d60</gtr:id><gtr:otherNames>Xu TR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>pm_15132_22_22389503</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58EB7204-F685-4670-9DB0-A683C3EAF67C</gtr:id><gtr:title>Real-time monitoring of redox changes in the mammalian endoplasmic reticulum.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ddbb4504c3f4657b59965da1f0e1e72b"><gtr:id>ddbb4504c3f4657b59965da1f0e1e72b</gtr:id><gtr:otherNames>van Lith M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>Q45LQd118mF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FBA2F229-5715-496F-A45D-8F6D2F7B0B94</gtr:id><gtr:title>Identification of three residues essential for 5-hydroxytryptamine 2A-metabotropic glutamate 2 (5-HT2A&amp;middot;mGlu2) receptor heteromerization and its psychoactive behavioral function.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f97c1e5aa46f403f33c523350ed7005"><gtr:id>4f97c1e5aa46f403f33c523350ed7005</gtr:id><gtr:otherNames>Moreno JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>pm_15132_22_23129762</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9C9C530-C503-4635-9BAF-AB02CA649CBB</gtr:id><gtr:title>Structural and biophysical characterisation of G protein-coupled receptor ligand binding using resonance energy transfer and fluorescent labelling techniques.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ca60e302065b8bcff5997ea08ec5c15"><gtr:id>4ca60e302065b8bcff5997ea08ec5c15</gtr:id><gtr:otherNames>Ward RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>pm_15132_22_23590995</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34B0ACF2-D29E-419F-A2C7-CE1EF7F57140</gtr:id><gtr:title>GPCR oligomerization and receptor trafficking.</gtr:title><gtr:parentPublicationTitle>Methods in enzymology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ca60e302065b8bcff5997ea08ec5c15"><gtr:id>4ca60e302065b8bcff5997ea08ec5c15</gtr:id><gtr:otherNames>Ward RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0076-6879</gtr:issn><gtr:outcomeId>pm_15132_22_23351734</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C158F00C-59D8-4871-9070-59848CA8E301</gtr:id><gtr:title>Functional homomers and heteromers of dopamine D2L and D3 receptors co-exist at the cell surface.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a687b56cf345f0ba3fa890abf870ba50"><gtr:id>a687b56cf345f0ba3fa890abf870ba50</gtr:id><gtr:otherNames>Pou C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>pm_15132_22_22291025</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A34A1298-B197-4FB7-811C-3BF5DC9157F1</gtr:id><gtr:title>G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives.</gtr:title><gtr:parentPublicationTitle>Pharmacological reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da94eb0da32979e66e69c2d6e3909000"><gtr:id>da94eb0da32979e66e69c2d6e3909000</gtr:id><gtr:otherNames>Ferr? S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0031-6997</gtr:issn><gtr:outcomeId>pm_540e168e168dd0a7c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08E82893-8055-43DC-89B3-6E1B6DD45619</gtr:id><gtr:title>Ligand-induced internalization of the orexin OX(1) and cannabinoid CB(1) receptors assessed via N-terminal SNAP and CLIP-tagging.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ca60e302065b8bcff5997ea08ec5c15"><gtr:id>4ca60e302065b8bcff5997ea08ec5c15</gtr:id><gtr:otherNames>Ward RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>Y5rS7Bubgkz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C66EB84D-69DE-4B85-9B33-02C9F5E8F7BD</gtr:id><gtr:title>Ligand regulation of the quaternary organization of cell surface M3 muscarinic acetylcholine receptors analyzed by fluorescence resonance energy transfer (FRET) imaging and homogeneous time-resolved FRET.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24eacfe11ef8c8ae4c17ba1fcf5035eb"><gtr:id>24eacfe11ef8c8ae4c17ba1fcf5035eb</gtr:id><gtr:otherNames>Alvarez-Curto E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>DUwDYmXuewY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6003452-0951-4B89-BB1D-E5C4B38B9DAD</gtr:id><gtr:title>Analysis of Human Dopamine D3 Receptor Quaternary Structure.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64ab31febd34133fa4d5127fdc0f0da5"><gtr:id>64ab31febd34133fa4d5127fdc0f0da5</gtr:id><gtr:otherNames>Marsango S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>5675e3988ea6c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F046DBFD-03A5-40B3-8050-6DACB609979E</gtr:id><gtr:title>The molecular basis of oligomeric organization of the human M3 muscarinic acetylcholine receptor.</gtr:title><gtr:parentPublicationTitle>Molecular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1018e6f6aa930fdba8a5dfed2d885dc6"><gtr:id>1018e6f6aa930fdba8a5dfed2d885dc6</gtr:id><gtr:otherNames>Liste MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0026-895X</gtr:issn><gtr:outcomeId>5675e0cb84b35</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>022C93A0-0982-43AE-B775-2B9F29CCE946</gtr:id><gtr:title>Distinct Agonist Regulation of Muscarinic Acetylcholine M2-M3 Heteromers and Their Corresponding Homomers.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f297ea7bd62c856f9256cedd8d5f3865"><gtr:id>f297ea7bd62c856f9256cedd8d5f3865</gtr:id><gtr:otherNames>Aslanoglou D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>5675e3566189f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99BF5D10-1C51-4897-8199-FF2A4586E5E7</gtr:id><gtr:title>Dynamic Regulation of Quaternary Organization of the M1 Muscarinic Receptor by Subtype-selective Antagonist Drugs.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11d822127d5c2f81e01d76980abe01b3"><gtr:id>11d822127d5c2f81e01d76980abe01b3</gtr:id><gtr:otherNames>Pediani JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>585d373c0bbc44.82476829</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDEEBC55-887B-4469-9A42-95867DEEB886</gtr:id><gtr:title>Applications of fluorescence and bioluminescence resonance energy transfer to drug discovery at G protein coupled receptors.</gtr:title><gtr:parentPublicationTitle>Analytical and bioanalytical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24eacfe11ef8c8ae4c17ba1fcf5035eb"><gtr:id>24eacfe11ef8c8ae4c17ba1fcf5035eb</gtr:id><gtr:otherNames>Alvarez-Curto E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1618-2642</gtr:issn><gtr:outcomeId>quhFyU5LYfw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10FDCD48-71D9-4849-B2BB-96A5693DF01C</gtr:id><gtr:title>Allosteric signaling through an mGlu2 and 5-HT2A heteromeric receptor complex and its potential contribution to schizophrenia.</gtr:title><gtr:parentPublicationTitle>Science signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f97c1e5aa46f403f33c523350ed7005"><gtr:id>4f97c1e5aa46f403f33c523350ed7005</gtr:id><gtr:otherNames>Moreno JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1945-0877</gtr:issn><gtr:outcomeId>56b3104e4b8589.46795791</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FDAFDE33-3BCA-4E82-AB4E-604EEE08F85A</gtr:id><gtr:title>Roundabout 1 exists predominantly as a basal dimeric complex and this is unaffected by binding of the ligand Slit2.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56b5789bc5a573cf9559163b8133b97d"><gtr:id>56b5789bc5a573cf9559163b8133b97d</gtr:id><gtr:otherNames>Zakrys L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>54576578ea3163.13106185</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED18E73F-0FF4-4ECE-BE22-46D2235DFF52</gtr:id><gtr:title>Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes.</gtr:title><gtr:parentPublicationTitle>Pharmacological reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70e47eafd29e227b2f9ea6213208387b"><gtr:id>70e47eafd29e227b2f9ea6213208387b</gtr:id><gtr:otherNames>Smith NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0031-6997</gtr:issn><gtr:outcomeId>B05A1E93_AB05A1E93_A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3FF49214-7B8E-4742-B38A-9081FDD2D390</gtr:id><gtr:title>The orexin OX(1) receptor exists predominantly as a homodimer in the basal state: potential regulation of receptor organization by both agonist and antagonist ligands.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bcc2284555def528ab993e8adea04d60"><gtr:id>bcc2284555def528ab993e8adea04d60</gtr:id><gtr:otherNames>Xu TR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>tFeGK3DSJku</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80178ACF-9229-4C82-A0F4-2C7E2D902F9C</gtr:id><gtr:title>The muscarinic M3 acetylcholine receptor exists as two differently sized complexes at the plasma membrane.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce4e60f10767a0f122d310cd622efd24"><gtr:id>ce4e60f10767a0f122d310cd622efd24</gtr:id><gtr:otherNames>Patowary S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>pm_15132_22_23521066</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2FF10475-F1CA-46EB-BE7E-992B07620E05</gtr:id><gtr:title>The role of dimerisation in the cellular trafficking of G-protein-coupled receptors.</gtr:title><gtr:parentPublicationTitle>Current opinion in pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85edc80268ea9bd4f3ba733ee9f05be5"><gtr:id>85edc80268ea9bd4f3ba733ee9f05be5</gtr:id><gtr:otherNames>Milligan G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1471-4892</gtr:issn><gtr:outcomeId>ZsVQWsVvfpH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47B7F329-62C7-4305-8844-B0904D3E1FCE</gtr:id><gtr:title>Developing chemical genetic approaches to explore G protein-coupled receptor function: validation of the use of a receptor activated solely by synthetic ligand (RASSL).</gtr:title><gtr:parentPublicationTitle>Molecular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24eacfe11ef8c8ae4c17ba1fcf5035eb"><gtr:id>24eacfe11ef8c8ae4c17ba1fcf5035eb</gtr:id><gtr:otherNames>Alvarez-Curto E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0026-895X</gtr:issn><gtr:outcomeId>pm_15132_22_21880827</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7CB43CD-D108-439D-B446-99F917E66CE2</gtr:id><gtr:title>Muscarinic receptor oligomerization.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64ab31febd34133fa4d5127fdc0f0da5"><gtr:id>64ab31febd34133fa4d5127fdc0f0da5</gtr:id><gtr:otherNames>Marsango S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn><gtr:outcomeId>5a66186c5e7883.47996743</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>264E7FB8-64B2-472A-8394-D2CEF4C327DA</gtr:id><gtr:title>Heteromultimerization of cannabinoid CB(1) receptor and orexin OX(1) receptor generates a unique complex in which both protomers are regulated by orexin A.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ca60e302065b8bcff5997ea08ec5c15"><gtr:id>4ca60e302065b8bcff5997ea08ec5c15</gtr:id><gtr:otherNames>Ward RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>oLBucKRJyfN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED3AD017-D948-44DB-BE8A-219CB2BDE4B0</gtr:id><gtr:title>Novel role for proteinase-activated receptor 2 (PAR2) in membrane trafficking of proteinase-activated receptor 4 (PAR4).</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63355bdc524cf1f2c6a5ce10a152d7b5"><gtr:id>63355bdc524cf1f2c6a5ce10a152d7b5</gtr:id><gtr:otherNames>Cunningham MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>pm_15132_22_22411985</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD990788-1274-4BA5-AF95-B57F2CD07B4D</gtr:id><gtr:title>Heterodimerisation of G protein-coupled receptors: implications for drug design and ligand screening.</gtr:title><gtr:parentPublicationTitle>Expert opinion on drug discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3739612b283a616c1b5d8afadb92626d"><gtr:id>3739612b283a616c1b5d8afadb92626d</gtr:id><gtr:otherNames>Saenz del Burgo L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1746-0441</gtr:issn><gtr:outcomeId>rDbkB4pZyAB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12A9B11A-9FB9-4494-83DB-5DE8C9EBAF97</gtr:id><gtr:title>Approaches to Characterize and Quantify Oligomerization of GPCRs.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64ab31febd34133fa4d5127fdc0f0da5"><gtr:id>64ab31febd34133fa4d5127fdc0f0da5</gtr:id><gtr:otherNames>Marsango S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>56b312d40ec814.28812458</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5A42E6D-2249-4797-8D5C-D6B7FA494976</gtr:id><gtr:title>Regulation of oligomeric organization of the serotonin 5-hydroxytryptamine 2C (5-HT2C) receptor observed by spatial intensity distribution analysis.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ca60e302065b8bcff5997ea08ec5c15"><gtr:id>4ca60e302065b8bcff5997ea08ec5c15</gtr:id><gtr:otherNames>Ward RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>5675e18ee8470</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0900050</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>